SG10201902831UA - Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers - Google Patents
Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducersInfo
- Publication number
- SG10201902831UA SG10201902831UA SG10201902831UA SG10201902831UA SG10201902831UA SG 10201902831U A SG10201902831U A SG 10201902831UA SG 10201902831U A SG10201902831U A SG 10201902831UA SG 10201902831U A SG10201902831U A SG 10201902831UA SG 10201902831U A SG10201902831U A SG 10201902831UA
- Authority
- SG
- Singapore
- Prior art keywords
- kits
- methods
- compositions
- stress protein
- acquired cytoresistance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Dentistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERS The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin Bl and, optionally, agents that impact heme protein metabolism. Figure for publication: None 104
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057047P | 2014-09-29 | 2014-09-29 | |
| US201562212232P | 2015-08-31 | 2015-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201902831UA true SG10201902831UA (en) | 2019-04-29 |
Family
ID=55631749
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201902831UA SG10201902831UA (en) | 2014-09-29 | 2015-09-28 | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
| SG11201702080UA SG11201702080UA (en) | 2014-09-29 | 2015-09-28 | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702080UA SG11201702080UA (en) | 2014-09-29 | 2015-09-28 | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10639321B2 (en) |
| EP (2) | EP3200582B1 (en) |
| JP (3) | JP6894837B2 (en) |
| KR (2) | KR102578217B1 (en) |
| CN (2) | CN112057470B (en) |
| AU (2) | AU2015324103C1 (en) |
| BR (1) | BR112017006531B1 (en) |
| CA (2) | CA2963089C (en) |
| DK (1) | DK3200582T3 (en) |
| ES (1) | ES2974905T3 (en) |
| FI (1) | FI3200582T3 (en) |
| HR (1) | HRP20240229T1 (en) |
| HU (1) | HUE065216T2 (en) |
| IL (3) | IL287607B (en) |
| LT (1) | LT3200582T (en) |
| MX (1) | MX2017004148A (en) |
| NZ (1) | NZ729754A (en) |
| PL (1) | PL3200582T3 (en) |
| PT (1) | PT3200582T (en) |
| RS (1) | RS65182B1 (en) |
| SG (2) | SG10201902831UA (en) |
| SI (1) | SI3200582T1 (en) |
| WO (1) | WO2016053882A2 (en) |
| ZA (1) | ZA202305280B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ729754A (en) | 2014-09-29 | 2023-01-27 | Hutchinson Fred Cancer Res | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
| US20190358242A1 (en) * | 2017-02-08 | 2019-11-28 | Fred Hutchinson Cancer Research Center | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
| CN111936059A (en) * | 2018-03-27 | 2020-11-13 | 精密科学公司 | Method for stabilizing haemoglobin and reagent for carrying out said method |
| WO2019227055A1 (en) * | 2018-05-24 | 2019-11-28 | Renibus Therapeutics, Inc. | Methods of treating patients at risk for renal injury and renal failure |
| SI3930686T1 (en) | 2019-02-28 | 2023-11-30 | Renibus Therapeutics, Inc. | Novel iron compositions and methods of making and using the same |
| US20230346823A1 (en) * | 2020-07-22 | 2023-11-02 | Niigata University | Utilization of vitamin b12 in inhibiting renal disorder |
| US20220079984A1 (en) * | 2020-09-11 | 2022-03-17 | Renibus Therapeutics, Inc. | Method for treating cancer with kidney protection |
| JP7412723B2 (en) * | 2021-03-12 | 2024-01-15 | 国立大学法人 新潟大学 | Suppression of renal damage induced by rhabdomyolysis |
| CN116472037A (en) * | 2021-03-12 | 2023-07-21 | 国立大学法人新潟大学 | Inhibition of renal injury induced by hemolytic reaction |
| US12042501B2 (en) | 2021-07-12 | 2024-07-23 | Renibus Therapeutics, Inc. | Metal protoporphyrin for treatment of BK virus |
| CN114891707B (en) * | 2022-05-20 | 2024-04-05 | 中国科学院微生物研究所 | Recombinant strain and method for producing bilirubin by whole cell catalysis thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579533A (en) | 1968-03-18 | 1971-05-18 | Antioch College | Preparation of porphin,substituted porphin and metal chelates thereof |
| GB1596298A (en) | 1977-04-07 | 1981-08-26 | Morgan Ltd P K | Method of and apparatus for detecting or measuring changes in the cross-sectional area of a non-magnetic object |
| US4692440A (en) | 1985-03-25 | 1987-09-08 | The Rockefeller University | Therapeutic use of tin mesoporphyrin |
| US4657902A (en) | 1985-03-25 | 1987-04-14 | The Rockefeller University | Therapeutic use of tin mesoporphyrin |
| US4668670A (en) | 1986-06-20 | 1987-05-26 | The Rockefeller University | Tin diiododeuteroporphyrin and therapeutic use thereof |
| US4782049A (en) | 1986-12-08 | 1988-11-01 | The Rockefeller University | Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis |
| WO1992016221A1 (en) | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
| US5274090A (en) | 1992-11-09 | 1993-12-28 | The Board Of Trustees Of The Leland Stanford Junior University | Tetraphenylporphyrin compounds and method |
| AU7103594A (en) | 1993-06-14 | 1995-01-03 | Rockefeller University, The | Treatment of neonatal hyperbilirubin with metalloporphyrin |
| DE19502255C2 (en) * | 1995-01-25 | 1996-11-28 | Windmoeller & Hoelscher | Device for applying notes from plastic film on flat workpieces |
| US5804551A (en) * | 1996-11-12 | 1998-09-08 | Baxter International Inc. | Pretraumatic use of hemoglobin |
| US20100293669A2 (en) | 1999-05-06 | 2010-11-18 | Jingdong Liu | Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| AU4243400A (en) | 1999-10-15 | 2001-04-30 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging agents and as antitumor agents |
| US6573258B2 (en) | 2000-09-27 | 2003-06-03 | Frontier Scientific, Inc. | Photodynamic porphyrin antimicrobial agents |
| US6517492B2 (en) | 2001-02-22 | 2003-02-11 | Texon Technologies Ltd. | Method and apparatus for assessment of cardiac function by monitoring movement of the trachea |
| AR037699A1 (en) | 2001-12-04 | 2004-12-01 | Monsanto Technology Llc | TRANSGENIC CORN WITH IMPROVED PHENOTYPE |
| CA2487426C (en) | 2002-06-04 | 2010-09-07 | Wellspring Pharmaceutical Corporation | Preparation of metal mesoporphyrin halide compounds |
| US7375216B2 (en) | 2002-06-04 | 2008-05-20 | Infacare Pharmaceutical Corporation | Preparation of metal mesoporphyrin compounds |
| EP2270166A3 (en) | 2002-09-18 | 2011-08-10 | Mendel Biotechnology, Inc. | Polynucleotides and polypeptides in plants |
| AU2003286474A1 (en) | 2002-10-18 | 2004-05-04 | The General Hospital Corporation | Compositions, solutions, and methods used for transplantation |
| JP2004307404A (en) * | 2003-04-08 | 2004-11-04 | Nipro Corp | Pharmaceutical composition containing artificial oxygen transporter |
| US7008937B2 (en) | 2003-06-10 | 2006-03-07 | Frontier Scientific, Inc. | Porphyrins and metalloporphyrins for inhibiting heme iron uptake |
| US7067659B2 (en) | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
| EP2661963B1 (en) * | 2004-05-06 | 2015-09-16 | The Trustees of Columbia University in the City of New York | Method for diagnosing acute renal failure or chronic renal failure |
| US20090092550A1 (en) | 2004-07-15 | 2009-04-09 | The University Of Sydney | Porphyrin linked metronidazole against gum disease: porphyromonas gingivalis |
| US7585527B2 (en) | 2005-09-19 | 2009-09-08 | Bala Venkataraman | Composition and method for treating iron deficiency anemia |
| PL2079472T3 (en) | 2006-10-04 | 2012-01-31 | Infacare Pharmaceutical Corp | High-purity large-scale preparation of stannsoporfin |
| US20080317725A1 (en) | 2007-06-20 | 2008-12-25 | Baum Seth J | Compositions and methods of treating chronic kidney disease |
| WO2009029836A2 (en) * | 2007-08-31 | 2009-03-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes |
| ES2609110T3 (en) | 2011-03-30 | 2017-04-18 | Infacare Pharmaceutical Corporation | Synthesis procedures of metallic mesoporphyrins |
| CN103355655A (en) * | 2012-03-30 | 2013-10-23 | 北京因科瑞斯医药科技有限公司 | Composition with alimentary anemia improving function and preparation method of composition |
| US9350026B2 (en) | 2012-09-28 | 2016-05-24 | Uchicago Argonne, Llc | Nanofibrous electrocatalysts |
| US20140273273A1 (en) * | 2012-11-01 | 2014-09-18 | Christie Mitchell Ballantyne | Biomarkers to improve prediction of heart failure risk |
| JP6573620B2 (en) | 2014-02-10 | 2019-09-11 | フレッド ハッチンソン キャンサー リサーチ センター | Halogen treatment for heart attack and ischemic injury |
| JP6523335B2 (en) | 2014-05-05 | 2019-05-29 | サントル ナシオナル ドゥ ラ ルシェルシュ シアンティフィーク（セーエヌエールエス） | Porphyrin molecular catalysts for selective electrochemical reduction of CO2 to CO |
| NZ729754A (en) | 2014-09-29 | 2023-01-27 | Hutchinson Fred Cancer Res | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
-
2015
- 2015-09-28 NZ NZ729754A patent/NZ729754A/en unknown
- 2015-09-28 HR HRP20240229TT patent/HRP20240229T1/en unknown
- 2015-09-28 CA CA2963089A patent/CA2963089C/en active Active
- 2015-09-28 CN CN202010969631.XA patent/CN112057470B/en active Active
- 2015-09-28 WO PCT/US2015/052676 patent/WO2016053882A2/en active Application Filing
- 2015-09-28 SG SG10201902831UA patent/SG10201902831UA/en unknown
- 2015-09-28 US US15/030,008 patent/US10639321B2/en active Active
- 2015-09-28 CA CA3220985A patent/CA3220985A1/en active Pending
- 2015-09-28 SG SG11201702080UA patent/SG11201702080UA/en unknown
- 2015-09-28 KR KR1020177011299A patent/KR102578217B1/en active Application Filing
- 2015-09-28 ES ES15846121T patent/ES2974905T3/en active Active
- 2015-09-28 KR KR1020237030842A patent/KR20230132636A/en not_active Application Discontinuation
- 2015-09-28 IL IL287607A patent/IL287607B/en unknown
- 2015-09-28 DK DK15846121.0T patent/DK3200582T3/en active
- 2015-09-28 RS RS20240188A patent/RS65182B1/en unknown
- 2015-09-28 FI FIEP15846121.0T patent/FI3200582T3/en active
- 2015-09-28 JP JP2017516840A patent/JP6894837B2/en active Active
- 2015-09-28 PT PT158461210T patent/PT3200582T/en unknown
- 2015-09-28 LT LTEPPCT/US2015/052676T patent/LT3200582T/en unknown
- 2015-09-28 MX MX2017004148A patent/MX2017004148A/en unknown
- 2015-09-28 EP EP15846121.0A patent/EP3200582B1/en active Active
- 2015-09-28 CN CN201580052330.8A patent/CN107072190B/en active Active
- 2015-09-28 HU HUE15846121A patent/HUE065216T2/en unknown
- 2015-09-28 EP EP23208291.7A patent/EP4327808A3/en active Pending
- 2015-09-28 AU AU2015324103A patent/AU2015324103C1/en active Active
- 2015-09-28 PL PL15846121.0T patent/PL3200582T3/en unknown
- 2015-09-28 BR BR112017006531-2A patent/BR112017006531B1/en active IP Right Grant
- 2015-09-28 SI SI201531991T patent/SI3200582T1/en unknown
-
2017
- 2017-01-06 US US15/400,690 patent/US9844563B2/en active Active
- 2017-03-29 IL IL251455A patent/IL251455B/en active IP Right Grant
-
2018
- 2018-08-29 US US16/116,411 patent/US10912793B2/en active Active
-
2020
- 2020-04-20 AU AU2020202652A patent/AU2020202652B2/en active Active
- 2020-05-25 IL IL274891A patent/IL274891B/en unknown
-
2021
- 2021-01-04 US US17/140,295 patent/US11878029B2/en active Active
- 2021-06-03 JP JP2021093465A patent/JP2021130710A/en active Pending
-
2022
- 2022-12-20 JP JP2022202892A patent/JP2023054797A/en active Pending
-
2023
- 2023-05-15 ZA ZA2023/05280A patent/ZA202305280B/en unknown
- 2023-09-12 US US18/465,768 patent/US20240108646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202305280B (en) | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers | |
| PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| EA201990566A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| BR112019000327A8 (en) | ANTICLAUDIN 18A2 ANTIBODY AND USE THEREOF | |
| EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
| NZ730563A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| MA40576B1 (en) | Anti-her2 antibodies and immunoconjugates | |
| EA201792616A1 (en) | MEANS, METHODS OF APPLICATION AND METHODS OF TREATMENT FOR SYNUCLEOPATHY | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| NZ715201A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MA40074A (en) | Multivalent ras binding compounds | |
| WO2016019134A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| EA201890747A1 (en) | METHODS OF TREATING INFLAMMATORY DISEASES | |
| MY190647A (en) | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof | |
| MY191539A (en) | Streptococcal vaccine | |
| WO2016073763A3 (en) | Beta-glucan methods and compositions that affect the tumor microenvironment | |
| MX2018011875A (en) | Enhanced direct cardiac reprogramming. | |
| EA201890753A1 (en) | APPLICATION OF TRIENTINE FOR DELIVERY OF COPPER IN THE CHECKED TISSUE | |
| EP3702470A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| EA201990181A1 (en) | OBTAINING ACTIVATED CLOSTRIDIAL NEUROTOXINS | |
| MY186302A (en) | Beta-caseins and gut microbiota | |
| BR112017011490A2 (en) | method for treating ischemic or inflammatory condition in a patient's organ or tissue | |
| MA43426A (en) | COMPOSITIONS AND METHODS FOR ADMINISTERING THERAPEUTIC AGENTS |